Pompe disease is an autosomal recessive lysosomal storage disorder caused by disease-associated variants in the acid alpha-glucosidase (GAA) gene. The current Pompe mutation database provides a severity rating of GAA variants based on in silico predictions and expression studies. Here, we extended the database with clinical information of reported phenotypes. We added additional in silico predictions for effects on splicing and protein function and for cross reactive immunologic material (CRIM) status, minor allele frequencies, and molecular analyses. We analyzed 867 patients and 562 GAA variants. Based on their combination with a GAA null allele (i.e., complete deficiency of GAA enzyme activity), 49% of the 422 disease-associated variants could be linked to classic infantile, childhood, or adult phenotypes.
hypertrophic cardiomyopathy and general muscle weakness. Without therapy, these patients die within the first year of life. Patients with symptom onset at childhood or adulthood have a more slowly progressive disease, leading to mobility problems and respiratory difficulties, but generally without hypertrophic cardiomyopathy.
Most of these patients will become ventilator and wheelchair dependent at some point in time (Gungor & Reuser, 2013; Reuser, Hirschhorn, & Kroos, 2018; Schoser et al., 2015) .
The standard treatment for Pompe disease is enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA). In classic infantile Pompe disease, ERT reduces cardiac hypertrophy, improves survival, and helps to achieve important developmental milestones that were previously unmet (Chakrapani, Vellodi, Robinson, Jones, & Wraith, 2010; Kishnani et al., 2009; Van den Hout et al., 2000) .
Numerous studies in children and adults have shown improvement of muscle strength, stabilization of pulmonary function, decreased fatigue, and extended survival. However, there is variation in response and not all patients respond equally well (Broomfield et al., 2016; de Vries et al., 2012; Gungor et al., 2016; Hahn et al., 2018; Kuperus et al., 2017; Papadopoulos et al., 2017; Regnery et al., 2012; Stepien, Whitby, Roberts, & Sharma, 2015; Strothotte et al., 2010; van Capelle et al., 2010; .
Patients who do not produce detectable GAA protein are termed cross reactive immunologic material (CRIM) negative. In these patients, both alleles carry a CRIM negative variant, and the phenotype is per definition classic infantile. Whereas CRIM positive patients have at least one disease-associated GAA variant that allows expression of GAA protein, the protein produced is enzymatically inactive due to misfolding, defects in glycosylation, defects in intracellular routing to the lysosome, and so forth. The second allele in CRIM positive patients can contain either a CRIM positive or a CRIM negative GAA variant. CRIM positive patients who have no detectable GAA enzyme activity develop a classic infantile phenotype, whereas patients with a childhood or adult phenotype still retain some enzymatic activity and are therefore always CRIM positive. CRIM negative infants have a greater tendency to develop anti-GAA neutralizing antibodies compared to CRIM positive infants (Kishnani et al., 2010; van Gelder et al., 2016) . Therefore, it is important to establish the CRIM status of GAA variants.
The rapidly expanding number of GAA sequence variants that have been discovered over the past 15 years has provided the basis for the establishment of the Pompe disease mutation database at www.pompevariantdatabase.nl. The present version of the Pompe mutation database lists all known GAA variants and provides a prediction of pathogenicity based on results obtained by in silico prediction algorithms, from the measured effect on GAA synthesis and enzymatic function when expressed in vitro, and from the type of variant. This approach resulted in a rating system with six different categories ranging from "very severe" to "nonpathogenic" (M. M. A. Kroos et al., 2012) . Here, we have extended the in silico predictions by analyzing all GAA variants using Alamut software for effects on RNA processing and protein function, and used these in silico predictions as well as published data to report or predict CRIM status. We scrutinized the literature and report clinical phenotypes that are associated with GAA variants.
The results of our study described here have been included in the update of the Pompe mutation database, that will from now on be referred to as the "Pompe disease GAA variant database" under the link (www.pompevariantdatabase.nl). The improved database should help doctors, genetic counselors and scientists to better predict disease outcome in patients diagnosed with Pompe disease. As well as providing new insight into variant severity, it will also improve prediction of prognosis in newborn screening programs, and support decision-making on therapeutic intervention.
| METHODS

| Annotation of variants
Variant annotations and classification conform to recommendations of the human genome variation society (HGVS) according to update (den Dunnen et al., 2016 . NM_000152.3 was used as reference sequence for GAA mRNA. Annotation of variants present in intronic regions were based on the LRG_673 reference sequence. Position c.1 represents the first nucleotide of the translation start codon ATG located in exon 2. NP_000143.2 was used for annotation of GAA protein variants.
| Minor allele frequency and reference SNP number
Minor allele frequency (MAF) was examined using dbSNP, Exac, Genome of the Netherlands (GoNL), ESP, and HGVD, with 1 January 2017 as last entry. The MAF reported in the database was based on the highest MAF score seen in any of the aforementioned databases.
The link for the most recent information on MAF has been provided in the database. Reference SNP (RS) numbers, when available, are also provided.
| In silico prediction of pathogenicity
These were performed using Alamut software. Missense predictions were performed using Mutation Taster, SIFT, and Align GVGD.
| Splicing prediction
Splice variants were defined as intronic positions −1 and −2 relative to the canonical splice acceptor site, and intronic positions +1 and +2 relative to the canonical splice donor site. So far, all splice variants defined in this way had been listed as "very severe". To better evaluate variants' possible effect on pre-mRNA splicing, we reevaluated all variants using Alamut ® software and provided this information in the database (Algorithms used are listed in Table S1 ).
Splice predictions were deemed to potentially affect splicing when at least two of the five algorithms predicted more than a 10% difference NIÑO ET AL. | 1955 in splice site strength as described previously (Bergsma et al., 2015) . In some cases it was possible to use the literature to retrieve functional evidence of variants that affect splicing. These findings were added to the column "biochemical evidence of pathogenicity".
| Prediction of CRIM status
If CRIM status had been determined experimentally by endogenous protein (i.e., immunoblot) or RNA expression (i.e., RT-qPCR) analysis, this was indicated at the "variant info" page under "biochemical evidence of CRIM status" or "biochemical evidence of pathogenicity", respectively. We also predicted CRIM status based on the type of variant for all variants, and reported this in the database. Variants that caused a frame shift were predicted to be CRIM negative.
Missense variants were predicted to be CRIM positive, provided that no effect on splicing was predicted. Known and predicted splice variants were classified with an "unknown" CRIM status, unless experimental evidence was reported on expression of in-frame mRNA transcripts. Please note that a) all prediction need to be confirmed experimentally. For example, it is known that certain variants that cause a premature stop codon can escape nonsensemediated decay. In those cases, the actual CRIM status could be positive rather than negative. It is also known that splicing outcome is difficult to predict (e.g., see Bergsma et al., 2015) . b) the CRIM status of a patient is determined by two disease-associated variants, and all patients with symptom onset at childhood or adulthood have some residual GAA enzyme activity. For this reason, these patients always have a CRIM positive status, caused by the presence of at least one CRIM positive variant.
| Patient classification and phenotypic information
We classified published patient information based on the criteria stated in Gungor and Reuser (2013) . Patients were classified with classic infantile Pompe disease if they presented symptoms at or under 12 months of age, and had evident signs of a hypertrophic cardiomyopathy (cardiac enlargement visible on chest X-ray, evidence of hypertrophy by echography). Patients were classified with childhood Pompe disease if the age of symptom onset was before 18 years of age and evident hypertrophic cardiomyopathy was absent. Patients were classified with adult Pompe disease if the first symptoms presented at the age of 18 years or later. If specific clinical information was reported in the literature, it was included in the database as indicated. Since familial connections were not always clearly stated in publications, no familial connections were taken into account and all cases were reported independently. We did all we could to avoid duplicating patients who had been described in more than one publication. It nonetheless remains possible that some duplicate cases were not detected.
| Availability of the data
The open access Pompe disease GAA variant database is available at www.pompevariantdatabase.nl.
In addition, all variants and patient phenotypes associated with the variants are included in the Leiden Open Variation Database (LOVD) at www.LOVD.nl/GAA.
| RESULTS
| Overview of the updated Pompe database
A flow chart for the criteria used for clinical severity rating is given in Figure 1a . Clinical severity rating of variants was performed based on patients with two identified GAA variants, at least one of which was a null allele, which is defined as a GAA variant who's protein product lacks any detectable GAA enzyme activity. The classification of null alleles (listed in Table S2 ) was made based on their association with the classic infantile phenotype. In some cases data have been reported that are derived from site directed mutagenesis of GAA expression constructs, but no patients have been reported that have such variant. In those cases, the clinical phenotype was classified as "unknown". When patients were reported but the second GAA allele was not a null allele, was not reported or had an unknown severity, the clinical phenotype was classified as unknown (disease-associated). In those cases, the (Table S3 ).
| Analysis of GAA variants based on clinical phenotype
Of the total number of 562 described variants, 422 are listed as disease-associated. We analyzed types of GAA variants according to their RNA and protein nomenclature (HGVS version 2016), and stratified these based on the clinical phenotype, being classic infantile, childhood, or adult ( Figure 2 ). The variants present in a total of 867 patients were analyzed ( Figure S2 ). In 49% of patients with Pompe disease reported in the mutation database (data not shown), the second GAA allele contained a null allele, and these patients were used for clinical severity rating of GAA variants. The reason for this is as follows. Usually, the second allele is a null allele, from which no residual GAA enzyme activity is produced. Any residual GAA enzyme activity is caused by the first allele. In this way, the disease-associated variant on the first allele can be rated. When the second allele would also have residual GAA enzyme activity, both alleles will contribute to the total residual GAA enzyme activity, and it would not be possible anymore to attribute the activity and the clinical severity rating to one of the two alleles. The remaining 140 of 562 GAA variants are classified as unknown (Table S4) Table S5 ). These variants have previously been shown to lower F I G U R E 2 Frequencies of GAA variants and patients with specific GAA variants, stratified for disease severity. (a) Frequencies of unique variants, classified at the RNA level (upper panel) and protein level (lower panel). The consequences of variants that affect pre-mRNA splicing was only included in specific categories (e.g., deletion, insertion, frameshift) at the protein level if experimental evidence was available. A list of all included categories is shown in Table S6 . (b) Frequencies of variant types in patients, classified at the RNA level (upper panel) and protein level (lower panel). Two GAA alleles per patient were counted. Please note that 1) only one GAA allele could be counted in patients with an unknown second GAA variant; and that 2) the allele was counted twice in patients with a homozygous genotype GAA enzymatic activity to some extent, however, they cannot cause Pompe disease (M.A. Shigeto et al., 2011; Swallow et al., 1989; van Diggelen et al., 2009 ).
First, we performed stratification of GAA variants. At the RNA level, substitutions were the predominant type of variants in all three phenotype groups. Other types of variants including splicing variants and deletions were present at a lower percentage without a clear trend relative to the phenotype. At the protein level, analysis of substitutions showed that the largest fraction was represented by missense variants, followed by nonsense variants, again without a clear trend relative to the phenotype. In 15% of cases, splicing prediction of disease-associated missense variants revealed possible effects on splicing ( Figure S1 ). The total number of unique variants was similar between the three phenotype groups and ranged from 134 in adult to 154 in childhood and 173 in classic infantile patients.
A different result was obtained when the number of patients with a certain type of variant was plotted per disease onset group. The variants in all patients with a known phenotype were analyzed ( Figure S2 ). We note that two GAA variants per patients were . This variant leads to partial or complete skipping of exon 2 during GAA pre-mRNA splicing, which has been described previously (Bergsma et al., 2015; Boerkoel et al., 1995; Dardis et al., 2014; Huie, Chen, Brooks, Grix, & Hirschhorn, 1994; van der Wal, Bergsma, Pijnenburg, van der Ploeg, & Pijnappel, 2017; van der Wal, Bergsma, van Gestel et al., 2017) . (Figure 3a,b) . At the RNA level, predominant categories for CRIM negative variants with experimental evidence were substitutions, splicing (splice donor site), deletions, and duplications (Figure 3a) . At the protein level, most of these variants were substitutions (nonsense) or frameshifts, both of which cause premature translation initiation sites, whereas substitutions (missense) were absent (Figure 3b ). For CRIM positive variants with experimental evidence, most variants were substitutions or splicing variants. At the protein level, most variants were classified as substitutions (missense) or deletions. A small fraction of CRIM positive variants were frameshifts, suggesting that in these cases the nonsense-mediated decay pathway did not completely degrade the mRNA.
| CRIM status of classic infantile variants
Prediction of CRIM status was performed on the basis of the variants' effects on the reading frame, but it should be noted that experimental validation is needed for these cases. 201 variants were predicted to be CRIM positive, and these were substitutions (missense) and deletions. Eighty-five GAA variants were predicted to be CRIM negative, the majority of which were frameshift and substitution (nonsense) variants. The total numbers of classified variants-that is those determined experimentally and those predicted-were 216 CRIM positive variants (62%) and 131 CRIM negative variants (38%). Figure S3 shows that disease-associated variants are distributed throughout the GAA RNA ( Figure S3A ) and protein ( Figure S3B ) with a slight enrichment in exons 4-16 relative to the flanking exons. A similar pattern was obtained when the distribution of variants was plotted along exons according to clinical severity ( Figure S3C ). For introns, disease-associated variants were found in all introns except for intron 5, without a clear pattern ( Figure S3D ). We note that intronic variants are rarely investigated at the functional level and that only the exon flanking regions are sequenced in standard diagnostic analysis.
| Distribution of disease-associated variants along the GAA gene
However, mapping of disease-associated substitution (missense) variants to functional GAA protein domains (Figure 4a ), showed a strong enrichment (up to seven-fold) in the catalytic sites relative to the N-terminal signal peptide and the C-terminal distal β-sheet ( Figure 4b ). Variants associated with the classic infantile phenotype showed a similar enrichment in the catalytic sites. When GAA variants in ExAC and dbSNP databases (which contains both diseaseassociated and non disease-associated variants) were plotted, no such enrichment in the catalytic domain was observed (Figure 4c ).
These results are in line with the critical function of the catalytic core for GAA enzyme activity. Table 1 shows the most common disease-associated variants per severity (when combined with a null allele), their geographical distributions, and their linked phenotypes. We note that two CRIM negative alleles are required to give rise to a CRIM negative phenotype. * The c.1655T>C variant has been classified to be associated with the classic infantile phenotype, although we note that three patients have been reported that carry this variant and showed a childhood onset phenotype.
| Geographic distribution of the most common disease-associated GAA variants
patients have a late onset form of Pompe disease, at present it cannot be accurately predicted when symptoms will arise and how severe these will be. It is therefore important to collect the clinical information on specific disease-associated variants to better understand the genotype-phenotype relationships. These aspects are relevant for newborn screening programs and genetic counseling.
| In silico predictions
Whereas clinical information is crucial for judging the severity of GAA variants, in silico predictions can be helpful as they can provide part of the evidence that leads to determination of the severity of variants. In addition, in silico predictions can provide evidence for the underlying mechanism involved in the disruption of GAA enzyme activity. For example, splicing predictions can point to possible effects on splicing of variants that would normally not be suspected of such effects. In particular, missense variants are often not evaluated for their effect on splicing, whereas several reports have suggested that missense variants can often affect splicing (Lim, Ferraris, Filloux, Raphael, & Fairbrother, 2011; Soukarieh et al., 2016) . Also in Pompe disease, we recently described a missense variant (c.1075G>A; p.G359R) that appeared to be disease-associated mainly because it affects splicing rather than changing the amino acids sequence. The effect of this variant was predicted in silico, and this was experimentally confirmed (Bergsma et al., 2015) . On the other hand, predictions can also fail, such as is the case for the IVS1 variant, which has an experimentally confirmed effect on splicing that cannot be predicted in silico (Boerkoel et al., 1995; Dardis et al., 2014; Huie et al., 1994; van der Wal, Bergsma, Pijnenburg et al., 2017; van der Wal, Bergsma, van Gestel et al., 2017) . In addition, comparison of predictions of the severity of amino acid changes with expression studies revealed failure of at least two out of three prediction programs to predict the experimentally found deleterious effect on GAA enzyme activity. This was the case for the following GAA studies showed no effect on enzyme activity. These variants included c.
664G>A, c.2132C>G. Finally, it is known that the strength of unnatural transcription termination signals depends on the adjacent sequences and that such signal can be 'leaky', reinforcing the need for experimental confirmation (Dabrowski, Bukowy-Bieryllo, & Zietkiewicz, 2015) . In all these cases, it is important to know whether a variant has some residual enzyme activity, whether the GAA protein is still expressed, or whether it is completely deleterious. This is crucial to make a distinction between the classic infantile and late onset forms of Pompe disease, and within the classic infantile population, to distinguish between CRIM positive and CRIM negative patients.
| CRIM status
CRIM negative classic infantile patients generally have a poorer prognosis compared to CRIM positive classic infantile patients when treated with ERT. One of the explanations is the tendency of CRIM negative patients to form high antibody titers during ERT (Kishnani et al., 2010; van Gelder et al., 2016) . This can be explained by the lack of any endogenous GAA protein in CRIM negative patients, which results in the recognition of rhGAA by the immune system and the generation of rhGAA-specific antibodies. However, most CRIM positive patients with Pompe disease also develop anti-rhGAA antibodies, likely due to posttranslational differences between the endogenous GAA protein and rhGAA, although on average the antibody titers are lower in CRIM positive patients compared to CRIM negative patients (Kishnani et al., 2010; Poelman et al., 2018) .
Antibodies have the potential to interfere with ERT by binding to rhGAA and thereby neutralizing its activity and/or uptake by muscle cells. This has led to the exploration of immune modulating strategies before the start of ERT in classic infantile patients (Elder et al., 2013; Mendelsohn, Messinger, Rosenberg, & Kishnani, 2009; Messinger et al., 2012) should also include splicing analysis (Bergsma, van der Wal, Broeders, van der Ploeg, & Pim Pijnappel, 2018) , such as the splicing assay for GAA that has been reported by us previously (Bergsma et al., 2015) .
| MAF
The extended database now also includes information on the MAF of variants. In general, a MAF of <1% is required for a variant to be considered disease-associated, because otherwise there would be many more patients then found in reality. Relatively high MAFs can be seen in the case of certain disease-associated GAA variants that are more frequent. Sanofi Genzyme); and ATB200/AT2221 (made by Amicus), which combines rhGAA with a chaperone to improve the stability of ERT.
When used as single treatment without ERT, chaperones could be used to treat a subpopulation of Pompe patients with certain missense variants by preventing degradation of endogenous GAA by the endoplasmatic reticulum-associated protein degradation pathway. The structure of rhGAA, which was solved recently (Roig-Zamboni et al., 2017) , should aid the design of next generation chaperones for personalized treatment, a process that will be greatly supported by information in the Pompe mutation database. When disease-associated missense variants were mapped on the GAA structure, we found enrichment of deleterious variants in the catalytic domain, which is important for GAA enzyme activity. The signal peptide/propeptide is involved in protein targeting and activation (Choo, Tan, & Ranganathan, 2005) , while the trefoil domain is found in a number of extracellular proteins (http://pfam.xfam.org/family/PF00088) and forms a secondary substrate binding site (Roig-Zamboni et al., 2017) . Given their (potential) importance, it is surprising that a relatively low percentage of disease-associated missense variants was found in the signal peptide/propeptide and trefoil domains.
Nevertheless, these domains also contained deleterious variants, which may be relevant for the idea that chaperones could be designed for trefoil domain variants that would have enhanced specificity compared to catalytic domain chaperones, because the catalytic domain is conserved in neutral glycosidases that would mediate undesired side effects when targeted with a chaperone (Roig-Zamboni et al., 2017) . If approved, other potential therapies currently under preclinical development may, depending on the predicted phenotype, be the most suitable for certain types of Pompe patients. These include AAV-mediated gene therapy directed toward the diaphragm (Corti et al., 2017) Administrative Department of Science, Technology and Innovation
